GlassScriptPhysician profile
Mark R Akerson
NPI 1699720367
$15,361.05
in general payments reported to CMS, 2019-2025
56 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $2,144 · 2021: $2,301 · 2022: $2,439 · 2023: $2,404 · 2024: $2,243 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.09 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,417.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,028.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,004.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $928.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $904.06 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $783.96 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $749.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $683.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $606.66 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $463.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.48 | 2020-2025 | Ofev, Jardiance, Jascayd |
| Arbor Pharmaceuticals, INC. | $348.88 | 2019-2021 | |
| Allergan, INC. | $337.93 | 2019-2020 | |
| Astellas Pharma US INC | $321.62 | 2020-2024 | Veozah |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Akerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.